The Evaluation of the Seroprevalence of HBV and HCV Infections in Patients with Hemodialysis in Hatay City and the Assessment of Antibody Response to Hepatitis B Vaccination

Basit Öğe Kaydı
dc.contributor.authorEvirgen, Omer
dc.contributor.authorOnlen, Yusuf
dc.contributor.authorMotor, Vicdan Koksaldi
dc.contributor.authorMahsereci, Erkan
dc.contributor.authorInci, Melek
dc.contributor.authorSahin, Sule
dc.date.accessioned2024-09-18T20:26:39Z
dc.date.available2024-09-18T20:26:39Z
dc.date.issued2010
dc.departmentHatay Mustafa Kemal Ãœniversitesien_US
dc.description.abstractPatients with end stage renal disease (ESRD) being treated with hemodialysis (HD) usually require frequent blood transfusions and hospitalizations. Therefore, they are at high risk of hepatitis. Because of infection control programs and regular vaccinations in dialysis centers, a decrease in the prevalence of hepatitis due to HBV and HCV infections is observed in these units. The present study aimed to investigate the seroprevalence of HBV and HCV infections in patients with HD in dialysis centers of Hatay city and to assess antibody response to hepatitis B vaccination. A total of 801 HD patients were included in the study between January 01 and December 31, 2009 from seven HD centers. Data were obtained from the files retrospectively. HBsAg, anti-HBs and anti-HCV seropositivity of the patient's samples were analyzed by enzyme immunoassay method. Of the 801 HD patients included, 480 (59.9%) were male and 321 (40.1%) were female. The mean age of the patients was 58.2 +/- 14.9 years (range, 10-98 years). HBsAg was positive in 29 (3.6%) patients and anti-HCV was positive in 76 (9.5%) patients. Five (0.6%) patients had both HBsAg and anti-HCV positivity. Of the 712 patients whose anti-HBs data were available, 578 (72.2%) patients were anti-HBs positive, whereas 134 (16.7%) were not. In the present study, although a lower hepatitis B and C prevalence was found in Hatay city compared with the previous studies conducted in Turkey, our results were similar reported for European countries. However, viral hepatitis is still an important health problem in HD patients. Infection control programs, vaccination, the education of the patients and health staff may decrease the incidence ofnewinfections.en_US
dc.identifier.endpage63en_US
dc.identifier.issn1307-9441
dc.identifier.issn2147-2939
dc.identifier.issue2en_US
dc.identifier.startpage57en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12483/10460
dc.identifier.volume16en_US
dc.identifier.wosWOS:000217180700003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isotren_US
dc.publisherGalenos Publ Houseen_US
dc.relation.ispartofViral Hepatit Dergisi-Viral Hepatitis Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHemodialysisen_US
dc.subjecthepatitis B virusen_US
dc.subjecthepatitis C virusen_US
dc.subjectseroprevalenceen_US
dc.subjectvaccinationen_US
dc.titleThe Evaluation of the Seroprevalence of HBV and HCV Infections in Patients with Hemodialysis in Hatay City and the Assessment of Antibody Response to Hepatitis B Vaccinationen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
Ä°sim:
Tam Metin / Full Text
Boyut:
290.09 KB
Biçim:
Adobe Portable Document Format
Ä°ndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu